Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma

NCT00418496 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Renal Cancer
Melanoma

Interventions

DRUG: Aldesleukin
DRUG: Sorafenib

Sponsor

Ohio State University Comprehensive Cancer Center

Collaborators

[object Object]
[object Object]